Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.
No Profit Forecast / Asset Valuations
No statement in this announcement constitutes a profit forecast for any period, nor should any statement be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for either Royalty Pharma or Elan as appropriate. No statement in this announcement constitutes an asset valuation.APPENDIX I: DefinitionsThe following definitions apply throughout this announcement unless the context otherwise requires:"Alkermes Shares"
the 7.75 million ordinary shares of Alkermes plc sold by Elan Science Three Limited on
February 6, 2013;
"BofA Merrill Lynch"
Merrill Lynch International, a subsidiary of Bank of America Corporation;
Biogen Idec Inc.;
"Board of Elan"
the board of directors of Elan at the date of this announcement;"Broker Median Price
the median of the price targets given by the brokers named in the Sources and Bases section
that have published price targets following the announcement of the Tysabri Transaction on
February 6, 2013 and prior to the Proposal Announc
|SOURCE RP Management, LLC|
Copyright©2012 PR Newswire.
All rights reserved